Rolipram

DRUG3 trials

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH), GlaxoSmithKline

Conditions

HealthyHuntington DiseaseMajor Depressive DisorderMultiple Sclerosis

Phase 1

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

CompletedNCT00369798

National Institute of Mental Health (NIMH)Healthy, Major Depressive Disorder

Start: 2006-08-02End: 2016-10-12Updated: 2018-07-05

Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

CompletedNCT01602900

GlaxoSmithKlineHuntington Disease

Start: 2011-11-22End: 2012-04-12Updated: 2017-06-20

Phase 2

Rolipram to Treat Multiple Sclerosis

CompletedNCT00011375

National Institute of Neurological Disorders and Stroke (NINDS)Multiple Sclerosis

Start: 2001-02-28End: 2004-04-30Target: 52Updated: 2008-03-04